BioApex was founded in 2008 as a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders including various cancers. We own a proprietary portfolio of small molecules compounds derived from plant hormones and natural xenobiotics, emanating from the research of Dr. Strnad and his group of scientists at the Palacký University in Olomouc, Czech Republic and in part from the Institute of Organic Chemistry, Warsaw, Poland. Our intellectual property addresses the very broad fields of cell cycle and senescence related disorders and, besides cancers, includes aging and inflammatory disorders. Our first group of compounds has very strong anticancer activities coupled with antiaging activities (a combination which is rather unusual). We believe that to date, there are no commercially available compounds that combine the same mode of action, effectiveness and minimal side effects.